loading
Neurobo Pharmaceuticals Inc stock is traded at $2.73, with a volume of 29,669. It is up +3.02% in the last 24 hours and down -18.99% over the past month. NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.
See More
Previous Close:
$2.65
Open:
$2.7925
24h Volume:
29,669
Relative Volume:
0.72
Market Cap:
$23.17M
Revenue:
-
Net Income/Loss:
$-12.47M
P/E Ratio:
-0.3075
EPS:
-8.877
Net Cash Flow:
$-10.85M
1W Performance:
-17.77%
1M Performance:
-18.99%
6M Performance:
-29.82%
1Y Performance:
+506.67%
1-Day Range:
Value
$2.65
$2.925
1-Week Range:
Value
$2.56
$3.50
52-Week Range:
Value
$0.38
$6.7499

Neurobo Pharmaceuticals Inc Stock (NRBO) Company Profile

Name
Name
Neurobo Pharmaceuticals Inc
Name
Phone
(857) 702-9600
Name
Address
545 CONCORD AVENUE, CAMBRIDGE, MA
Name
Employee
8
Name
Twitter
Name
Next Earnings Date
2024-08-12
Name
Latest SEC Filings
Name
NRBO's Discussions on Twitter

Neurobo Pharmaceuticals Inc Stock (NRBO) Upgrades & Downgrades

Date Action Analyst Rating Change
Jun-15-20 Initiated H.C. Wainwright Buy

Neurobo Pharmaceuticals Inc Stock (NRBO) Latest News

pulisher
Oct 01, 2024

NRBO stock touches 52-week low at $2.9 amid market challenges By Investing.com - Investing.com South Africa

Oct 01, 2024
pulisher
Oct 01, 2024

NRBO stock touches 52-week low at $2.9 amid market challenges - Investing.com India

Oct 01, 2024
pulisher
Oct 01, 2024

NRBO stock touches 52-week low at $2.9 amid market challenges - Investing.com

Oct 01, 2024
pulisher
Oct 01, 2024

NRBO stock touches 52-week low at $2.9 amid market challenges - Investing.com Canada

Oct 01, 2024
pulisher
Oct 01, 2024

NRBO: Positive SAD Part 1 Data; MAD Part 2 Results Expected in 1Q25… - Yahoo Finance

Oct 01, 2024
pulisher
Sep 30, 2024

NeuroBo reports positive early trial results for obesity drug - Investing.com

Sep 30, 2024
pulisher
Sep 30, 2024

NeuroBo reports positive early trial results for obesity drug - Investing.com India

Sep 30, 2024
pulisher
Sep 30, 2024

We're A Little Worried About NeuroBo Pharmaceuticals' (NASDAQ:NRBO) Cash Burn Rate - Yahoo Finance

Sep 30, 2024
pulisher
Sep 30, 2024

NeuroBo’s DA-1726 Shows Promise in Obesity Trial Phase 1 - TipRanks

Sep 30, 2024
pulisher
Sep 30, 2024

NeuroBo reports positive early trial results for obesity drug By Investing.com - Investing.com Australia

Sep 30, 2024
pulisher
Sep 30, 2024

NeuroBo reports positive early trial results for obesity drug By Investing.com - Investing.com UK

Sep 30, 2024
pulisher
Sep 25, 2024

Affinity Asset Advisors LLC Invests $432,000 in NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) - Defense World

Sep 25, 2024
pulisher
Sep 24, 2024

Nutkao, transaction in closing with Morocco's sovereign wealth fundEFA News - EFA News - European Food Agency

Sep 24, 2024
pulisher
Sep 24, 2024

Berkley W R Corp Boosts Holdings in Nabors Energy Transition Corp. II (NASDAQ:NETD) - MarketBeat

Sep 24, 2024
pulisher
Sep 24, 2024

Bank of Montreal Can Decreases Stock Position in Novo Nordisk A/S (NYSE:NVO) - Defense World

Sep 24, 2024
pulisher
Sep 23, 2024

National Bank of Canada (OTCMKTS:NTIOF) Hits New 1-Year High at $94.20 - Defense World

Sep 23, 2024
pulisher
Sep 23, 2024

70,000 Shares in Neurogene Inc. (NASDAQ:NGNE) Purchased by Integral Health Asset Management LLC - Defense World

Sep 23, 2024
pulisher
Sep 23, 2024

NVO Stock Down on Unsatisfactory Data From Mid-Stage Obesity Study - Yahoo Finance

Sep 23, 2024
pulisher
Sep 23, 2024

BMO maintains stock target on Novo Nordisk, cites trial results - Investing.com

Sep 23, 2024
pulisher
Sep 23, 2024

Lombard Odier Asset Management Europe Ltd Reduces Stock Position in nVent Electric plc (NYSE:NVT) - Defense World

Sep 23, 2024
pulisher
Sep 23, 2024

Avoro Capital Advisors LLC Makes New Investment in Neurogene Inc. (NASDAQ:NGNE) - Defense World

Sep 23, 2024
pulisher
Sep 21, 2024

National Bank of Canada (OTCMKTS:NTIOF) Increases Dividend to $0.81 Per Share - MarketBeat

Sep 21, 2024
pulisher
Sep 20, 2024

Amalgamated Bank Reduces Holdings in nVent Electric plc (NYSE:NVT) - Defense World

Sep 20, 2024
pulisher
Sep 20, 2024

Dong-A ST executives sell NeuroBo Pharmaceuticals shares worth over $1,500 - Investing.com

Sep 20, 2024
pulisher
Sep 20, 2024

Dong-A ST executives sell NeuroBo Pharmaceuticals shares worth over $1,500 - Investing.com UK

Sep 20, 2024
pulisher
Sep 20, 2024

BMO sustains stock target, outperform on Novo Nordisk amid trial results - Investing.com India

Sep 20, 2024
pulisher
Sep 20, 2024

Novo Nordisk Sinks on Obesity Drug Study's Disappointing Results - Investopedia

Sep 20, 2024
pulisher
Sep 20, 2024

What's Going On With NovaBay Pharmaceuticals Shares Friday? - Benzinga

Sep 20, 2024
pulisher
Sep 20, 2024

Novo Nordisk Stock Declines After Headline Results From Mid-Stage Study Of Monlunabant In Obese Patients - Yahoo Finance

Sep 20, 2024
pulisher
Sep 20, 2024

Novo Nordisk Shares Slide After Disappointing Obesity Pill Trial - Finimize

Sep 20, 2024
pulisher
Sep 20, 2024

Novo Nordisk shares drop more than 4% on disappointing obesity pill data - The Economic Times

Sep 20, 2024
pulisher
Sep 20, 2024

NVO Stock Loses Around $29B in 3 Months: Buy the Dip or Steer Clear? - Yahoo Finance

Sep 20, 2024
pulisher
Sep 20, 2024

TD Cowen Reiterates Buy Rating on Novo Nordisk (NVO) Following Monlunabant Obesity Update - StreetInsider.com

Sep 20, 2024
pulisher
Sep 20, 2024

Novo Nordisk shares drop nearly 5% on disappointing obesity pill data - Yahoo Finance

Sep 20, 2024
pulisher
Sep 20, 2024

Novo Shares Fall on Safety Data for New Weight-Loss Drug - BNN Bloomberg

Sep 20, 2024
pulisher
Sep 20, 2024

Novo drops to 1-month low after Monlunabant trial data - XM

Sep 20, 2024
pulisher
Sep 20, 2024

NeuroBo shareholders approve significant stock issuance By Investing.com - Investing.com Australia

Sep 20, 2024
pulisher
Sep 20, 2024

NeuroBo shareholders approve significant stock issuance - Investing.com India

Sep 20, 2024
pulisher
Sep 20, 2024

NeuroBo shareholders approve significant stock issuance By Investing.com - Investing.com Canada

Sep 20, 2024
pulisher
Sep 19, 2024

Novo Nordisk: The Street Is Not Seeing The Growth Acceleration Potential (NYSE:NVO) - Seeking Alpha

Sep 19, 2024
pulisher
Aug 21, 2024

NRBO: Data from Part 1 of Phase 1 Trial of DA-1726 in 3Q24… - Zacks Small Cap Research

Aug 21, 2024
pulisher
Aug 21, 2024

NRBO: Data from Part 1 of Phase 1 Trial of DA-1726 in 3Q24… - Yahoo Finance

Aug 21, 2024
pulisher
Aug 14, 2024

NeuroBo Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Update - citybiz

Aug 14, 2024
pulisher
Aug 14, 2024

NeuroBo Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits - Quantisnow

Aug 14, 2024
pulisher
Aug 14, 2024

NeuroBo Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Update - Longview News-Journal

Aug 14, 2024
pulisher
Aug 14, 2024

NeuroBo concludes subject enrolment in SAD portion of obesity treatment trial - Clinical Trials Arena

Aug 14, 2024
pulisher
Aug 14, 2024

NeuroBo concludes subject enrolment in SAD portion of obesity treatment trial - Yahoo Finance

Aug 14, 2024
pulisher
Aug 13, 2024

NeuroBo Completes First Phase 1 Enrollment for Obesity Drug Trial - TipRanks

Aug 13, 2024
pulisher
Aug 06, 2024

NeuroBo partners for long-acting obesity treatment - Investing.com India

Aug 06, 2024
pulisher
Aug 06, 2024

NeuroBo Partners for Monthly Dual-Action Diabetes Drug Development - TipRanks

Aug 06, 2024
pulisher
Aug 06, 2024

NeuroBo Pharmaceuticals Announces Joint Research Agreement, Together with Dong-A ST and ImmunoForge to Develop a Long-Acting Once-Monthly Formulation of DA-1726 for the Treatment of Obesity - StockTitan

Aug 06, 2024

Neurobo Pharmaceuticals Inc Stock (NRBO) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$23.49
price up icon 0.38%
$355.93
price up icon 1.67%
$60.20
price down icon 1.42%
$246.04
price up icon 5.31%
$122.68
price up icon 2.40%
$529.95
price down icon 2.40%
Cap:     |  Volume (24h):